Get the Stockscreener App
14.30
1.06%
+0.15
UroGen Pharma Ltd stock is currently priced at $14.30, with a 24-hour trading volume of 3,545.
It has seen a +1.06% increased in the last 24 hours and a -4.67% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.05 pivot point. If it approaches the $14.42 resistance level, significant changes may occur.
Previous Close:
$14.15
Open:
$14.22
24h Volume:
3,545
Market Cap:
$482.83M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-3.0556
EPS:
-4.68
Net Cash Flow:
$-76.57M
1W Performance:
-0.49%
1M Performance:
-4.67%
6M Performance:
+29.29%
1Y Performance:
+23.38%
1D Range:
$14.16
$14.29
52W Range:
$8.69
$24.13
UroGen Pharma Ltd Stock (URGN) Company Profile
Name
UroGen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HaTaasiya Street, Ra'anana
UroGen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
UroGen Pharma Ltd Stock (URGN) Latest News
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Zacks Investment Research
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
Zacks Investment Research
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Benzinga
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
UroGen Pharma Ltd Stock (URGN) Financials Data
UroGen Pharma Ltd (URGN) Revenue 2024
URGN reported a revenue (TTM) of $82.71 million for the quarter ending December 31, 2023, a +28.52% rise year-over-year.
UroGen Pharma Ltd (URGN) Net Income 2024
URGN net income (TTM) was -$102.24 million for the quarter ending December 31, 2023, a +6.87% increase year-over-year.
UroGen Pharma Ltd (URGN) Cash Flow 2024
URGN recorded a free cash flow (TTM) of -$76.57 million for the quarter ending December 31, 2023, a +12.80% increase year-over-year.
UroGen Pharma Ltd (URGN) Earnings per Share 2024
URGN earnings per share (TTM) was -$3.67 for the quarter ending December 31, 2023, a +23.22% growth year-over-year.
UroGen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '24 |
Sale |
15.74 |
4,993 |
78,590 |
18,824 |
| Schoenberg Mark | Chief Medical Officer |
Jan 31 '24 |
Sale |
15.74 |
3,789 |
59,639 |
149,423 |
| Smith Jason Drew | General Counsel |
Aug 31 '23 |
Sale |
18.01 |
3,800 |
68,438 |
18,407 |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
1.17%
Cap:
|
Volume (24h):